New direction recommended for isotope production

Collier, Roger
February 2010
CMAJ: Canadian Medical Association Journal;2/9/2010 Supplement, Vol. 182, pE115
Academic Journal
The article reports that Canada will move in the opposite direction of the approach on isotope production through MDS Nordion and Atomic Energy of Canada Ltd. (AECL). According to Alan J. Kuperman, director of the Nuclear Proliferation Prevention Program at the University of Texas, the 4 general recommendations are a rejection across-the-board of the Nordion/AECL approach. An overview of the recommendations on solving the problem is presented.


Related Articles

  • Reactor maintenance issue continues.  // Medical Device Daily;12/6/2007, Vol. 11 Issue 221, p8 

    The article announces that MDS Nordion has provided an update to its medical isotope consumers about a supply issue at Atomic Energy of Canada Ltd. (AECL). According to MDS Nordion, it has been notified by AECL that an additional extension of the maintenance shutdown at the National Research...

  • Canadian government is urged to build two isotope plants. Spurgeon, David // BMJ: British Medical Journal (Overseas & Retired Doctors Edition;6/13/2009, Vol. 338 Issue 7708, p1411 

    The article reports on the demand by MDS Nordion, a medical isotope company, for the Canadian government and Atomic Energy of Canada Ltd. to fulfil contractual obligations made in 1996 to build two isotope production reactors to replace the National Research Universal reactor. Atomic Energy...

  • Isotope maker calls for another look at scrapped reactors. Collier, Roger // CMAJ: Canadian Medical Association Journal;9/1/2009, Vol. 181 Issue 5, pE73 

    The article focuses on the call of MDS Nordion, the Canadian life sciences company, for the federal government to determine that it would fix 2 nuclear reactors that can produce medical isotopes in Canada. It cites that MDS Nordion hired Atomic Energy of Canada Ltd. (AECL) for the design and...

  • MDS Nordion.  // Contract Pharma;2010 Directory, Vol. 11 Issue 10, p146 

    The article profiles MDS Nordion, a leader in medical technology located in Ottawa, Ontario. It notes that MDS manufactures medical isotopes to facilitate diagnosis of diseases. Moreover, MDS offers solutions to radiopharmaceutical process, commercial manufacturing, and development of medical...

  • Isotope update. Kondro, Wayne // CMAJ: Canadian Medical Association Journal;8/10/2010, Vol. 182 Issue 11, pE523 

    The article reports that the Atomic Energy of Canada Ltd. has announced that its first medical isotopes will begin for processing and distribution within 10 days of the troubled National Research Universal reactor in Chalk River, Ontario being returned to service.

  • Nuclear-reactor closure hits cancer tests. Hoag, Hannah // Nature;12/13/2007, Vol. 450 Issue 7172, p926 

    The article reports on the closure of the National Research Universal (NRU) in Ontario, Canada due to its scheduled maintenance resulting to the cancellation of tests for cancer and heart disease because of shortage of medical isotopes. The maintenance includes the installation of safety-related...

  • Canada's nuclear fallout. Collier, Roger // CMAJ: Canadian Medical Association Journal;2/26/2008, Vol. 178 Issue 5, p536 

    The article focuses on the controversy regarding the nuclear reactor in Chalk River in Ontario, Canada, which produces the raw materials for medical isotopes. It notes that the controversy has become an international embarrassment for Canada while some European isotope producers has refused to...

  • MDS Nordion Ion Technologies.  // Medical Design Technology;Mar2002, Vol. 6 Issue 3, p19 

    Features the radiation technology company, MDS Nordion in Canada. Services offered by MDS; Development of irradiators for commercial applications; Participation of MDS in the Gamma Processing Seminar.

  • Companies to develop new cancer radiotracers.  // Medical Device Daily;6/28/2010, Vol. 14 Issue 123, p7 

    The article reports on an agreement signed by MDS Nordion, Guerbet and Cyron for the development of Positron Emission Tomography (PET) radiotracers for cancer diagnostics.


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics